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Abstract
Rationale – Fluoxetine improves affect in clinical syndromes such 
as depression and premenstrual dysphoric disorder. Little is known 
about fl uoxetine’s infl uence on mood changes after quitting smoking, 
which often resemble sub-clinical depression.
Objectives – The present study, a re-analysis of previously published 
data (Niaura et al. 2002), examined fl uoxetine’s effect on changes in 
negative and positive affect following quitting smoking.
Methods – Adult smokers (n = 175) without clinically signifi cant de-
pression were randomized on a double-blind basis to receive fl uox-
etine hydrochloride (30 or 60 mg daily) or placebo for 10 weeks in 
combination with cognitive-behavioral therapy (CBT) for smoking 
cessation. We postulated that fl uoxetine would benefi cially infl uence 
post-cessation changes in positive and negative affect.
Results – Mood change across treatment was analyzed using mixed 
linear modeling controlling for initial level of nicotine dependence, 
plasma fl uoxetine metabolites, and change in cotinine (a nicotine me-
tabolite) at each visit. Relative to placebo, those on 60 mg fl uoxetine 
experienced an elevation in positive affect that increased across time 
[t(526) = 2.50, P = 0.01], and a reduction in negative affect that re-
turned to baseline across time [t(524) = 2.26, P = 0.02]. There were 
no differences between 30 mg and placebo on changes in positive or 
negative affect.
Conclusions – Results indicate that 60 mg of fl uoxetine improves 
both positive and negative mood states after quitting smoking and 
that diminished positive affect may be an overlooked affective re-
sponse to smoking cessation.
Keywords
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Introduction
Abstaining from nicotine, even during short periods of time, 
is accompanied by a cluster of affective responses resembling 
sub-clinical depression (Gilbert et al. 1998). Irritability, anxi-
ety, and depressed mood, for example, are commonly reported 
mood disturbances that are experienced after quitting smoking 
(Hughes and Hatsukami 1986; American Psychiatric Associa-
tion 1994; Gilbert et al. 1998). Reductions in positive affect, 
however, have largely been overlooked as a possible response 
to smoking cessation. That neglect is surprising, given the in-
tegral relationship between defi cient positive mood states and 
depression (Clark and Watson 1991; Coyne 1994), and evi-
dence that quitting smoking heightens the risk of depressive 
episodes (Borrelli et al. 1996; Tsoh et al. 2002). Positive af-
fect declines after quitting smoking (Gilbert et al. 1998; Ler-
man et al. 2002; Cook et al. 2003) and persists across 30 days 
of abstinence (Gilbert et al. 1998). Further, empirical evidence 
that positive and negative affect are linked to different neural 
underpinnings (Davidson 1992) and have different psycholog-
ical correlates (Watson et al. 1988) supports the independence 
of these constructs. Thus, low positive affect may be an im-
portant and neglected response to quitting smoking, which, in 
combination with elevated negative affect, constitutes a dis-
tressing affective syndrome that follows smoking cessation.
Similarities between cessation-induced mood disturbance 
and other affective syndromes (e.g. depression, premenstrual 
dysphoric disorder) suggest that antidepressant medications 
might also ameliorate unpleasant mood states after quitting 
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smoking. A variety of antidepressants with dopaminergic, 
noradrenergic, and/or serotonergic actions have demonstrated 
effi cacy for promoting smoking cessation (Spring et al. 1995; 
Hurt et al. 1997; Hall et al. 1998; Niaura et al. 2002). Studies 
on the effects of the agents have, for the most part, focused 
on the alleviation of negative mood or depressive symp-
toms. Specifi cally, euthymic smokers treated with nortrypti-
line (catecholaminergic and serotonergic actions) or bupro-
pion (dopaminergic and noradrenergic actions), report lower 
levels of post-cessation negative affect than smokers who did 
not receive these treatments (Hall et al. 1998; Shiffman et al. 
2000; Lerman et al. 2002). Effects of antidepressants on pos-
itive affect are less understood (Zald and Depue 2001). Al-
though Shiffman et al. (2000) found that bupropion attenu-
ated a decrease in positive affect in euthymic smokers during 
72-h nicotine deprivation, Lerman and colleagues (2002) did 
not detect an effect of bupriopion on post-cessation positive 
moods.
The infl uence of fl uoxetine, a selective serotonin reuptake 
inhibiting antidepressant (SSRI), on mood following smoking 
cessation has yet to be examined. Although fl uoxetine, given 
for 3 weeks prior to a quit attempt reduced depression among 
euthymic smokers (Dalack et al. 1995), fl uoxetine’s effect 
on affective distress during nicotine abstinence remains un-
known. In other clinical syndromes, including major depres-
sion (Gram 1994), subsyndromal depression (Gram 1994), 
and premenstrual dysphoric disorder (Cohen et al. 2002), 
fl uoxetine has been shown to alleviate negative affect. In de-
pression, the drug’s mood benefi t is not confi ned to patients 
who present solely with depressed mood, but occurs also 
among patients with comorbid anxiety disorder (Sonawalla et 
al. 2002). In addition to engendering improvements in depres-
sion, fl uoxetine reduces a full range of negative moods, in-
cluding anxiety and anger-hostility (Sonawalla et al. 2002).
To our knowledge, there have been no prior studies ex-
amining whether fl uoxetine can prevent the dysphoric mood 
and the decreased positive affect that typically follow nicotine 
abstinence. There are, however, three reasons to expect such 
effects. First, similar preventive benefi ts have been demon-
strated for fl uoxetine as a treatment of premenstrual dysphoric 
disorder, such that the drug prevents intermittent worsening of 
negative mood (Cohen et al. 2002). Second, although fl uox-
etine has yet to be established as a treatment for smoking ces-
sation, it has been shown to yield a modest cessation advan-
tage to smokers who are trying to quit (Niaura et al. 2002), 
especially among those who have higher baseline levels of 
depressive symptomatology (Hitsman et al. 1999). Such ef-
fects might partly arise from the drug’s mood control proper-
ties. Third, administration of fl uoxetine and serotonin1A recep-
tor antagonist, p-MPPI, in rats prevents a rise in brain reward 
threshold during nicotine deprivation (i.e. reverses diminished 
responding to rewarding stimuli; Harrison et al. 2001). To the 
extent that diminished positive affect is associated with di-
minished reinforcing value of approach behavior to rewards 
(Depue and Collins 1999), fl uoxetine might buffer the losses 
in positive affect associated with quitting smoking.
The present study examined the effect of 30 and 60 mg 
fl uoxetine, relative to placebo, on acute change in positive and 
negative moods during nicotine abstinence. We postulated that 
fl uoxetine would buffer the increase, or even diminish nega-
tive affect during smoking cessation. Moreover, we postulated 
that fl uoxetine would buffer post-cessation losses in positive 
affect, or, potentially, increase positive affect during smoking 
cessation.
Materials and methods
Participants
Subjects were 175 euthymic male and female smokers recruited to 
three of 16 sites in a double-blind, placebo-controlled, multicenter 
trial examining the infl uence of fl uoxetine on smoking cessation. The 
present study is a re-analysis of previously published data (Niaura et 
al. 2002), and used the three-site subset that measured positive and 
negative affect across visits. Subjects’ mean age was 42.6 years (SD 
= 9.4). Most were female (57.1%), Caucasian (94.6%), and married 
(52.6%). Subjects averaged 30.1 cigarettes per day (SD = 12.9) for 
a mean of 25.1 years (SD = 9.1) prior to treatment. Enrollees were 
moderately dependent on cigarettes, as indicated by a mean score 
of 6.8 (SD = 1.8) on the Fagerstrom Tolerance Questionnaire (Fag-
erstrom 1978). At entry, cotinine, a nicotine metabolite, averaged 
288.7 ng/ml (SD = 152.9). Subject eligibility criteria, as well as the 
cessation outcomes of the multi-center trial, are reported elsewhere 
(Niaura et al. 2002).
Measures
Positive affect
Positive affect was assessed at each visit via the Positive and Nega-
tive Affect Scale (PANAS; Watson et al. 1988). The PANAS is a self-
report state mood questionnaire consisting of 20 adjectives that are 
rated on 5-point scales ranging from 1 (very slightly or not at all) to 
5 (extremely). The positive affect subscale, manifested by feelings of 
activation, elation, enthusiasm, and enjoyment, consists of 10 items, 
with potential scores ranging from 10 to 50. The Positive Affect sub-
scale has been shown to possess high internal consistency (Watson et 
al. 1988).
Negative affect
Negative affect was assessed at each visit via the negative affect sub-
scale of the PANAS (Watson et al. 1988). The negative affect scale, 
encompassing feelings of distress, hostility, nervousness, scorn, and 
gloominess, is comprised of ten words with scores ranging from 10 
to 50. The negative affect scale possesses high internal consistency 
(Watson et al. 1988).
Smoking characteristics
The eight-item Fagerstrom Tolerance Questionnaire (FTQ; Fag-
erstrom 1978) was administered to measure degree of behavioral 
responses suggestive of nicotine dependence (e.g. smoking many 
cigarettes, smokes early in the morning). Scores ranged from 0 
to 11, with higher values suggesting greater nicotine dependence. 
Correlations between the FTQ and measures of nicotine intake 
support the construct validity of the scale (Fagerstrom and Sch-
neider 1989).
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Saliva cotinine concentration was measured at each visit. Saliva 
cotinine samples were analyzed by SciCor Laboratory (Indianapolis, 
Ind., USA).
Carbon monoxide, assessed via an ecolyzer (Model EC-50, Vi-
talograph Corporation), was also assessed at each visit.
Medication compliance
Compliance was verifi ed by assays of plasma concentrations of 
fl uoxetine metabolites (fl uoxetine and norfl uoxetine) at visits 5 (3 
weeks after starting drug) and 9 (end of medication). Assays were 
performed after study completion using gas chromatography (Nash 
et al. 1992).
Axis I disorders
Axis I disorders were assessed via Structured Clinical Interview for 
DSM-IV, patient version (SCID; Spitzer et al. 1992). The SCID has 
moderate construct validity, as shown by its favorable comparison 
with other diagnostic assessment methods (Williams et al. 1992). In-
dividuals with current axis I disorders other than nicotine dependence 
were excluded from the sample.
Procedure
All study sites were approved by appropriate ethics committees. Par-
ticipants fi rst attended a screening session where they provided in-
formed consent and were assessed for axis I disorders via the SCID 
(Spitzer et al. 1992). Those who were eligible for the study began 
the fi rst of nine sessions of individual cognitive behavioral treatment 
aimed at achieving smoking cessation by the development of coping 
skills and relapse prevention. Subjects were randomized on a double-
blind basis to receive 10 weeks of placebo (n = 60), 30 mg (n = 57) 
or 60 mg (n = 58) of fl uoxetine, which began during the second visit. 
Participants quit smoking 14 days after the beginning of the med-
ication phase (just prior to visit 4), so that a therapeutic drug level 
would be achieved before quitting smoking. Assessments of positive 
and negative affect were collected at each visit.
Analytic plan
Mood change across seven time points (visits 3–9) was analyzed us-
ing mixed linear modeling, implemented via SAS PROC MIXED. 
Random effects regression models used random intercepts, linear and 
quadratic trend model with autoregressive errors. As recommended, 
this variance covariance structure for the longitudinal data was se-
lected after comparisons with several other potential structures (Ver-
becke and Molenberghs 2000). Nicotine dependence, change in coti-
nine, and fl uoxetine blood levels were utilized as covariates. Change 
in cotinine at each visit was analyzed as a time varying covariate, 
which statistically removed the infl uence of nicotine exposure on 
positive and negative affect across time. Both time and time squared 
terms were included in all analyses. Non-signifi cant interaction terms 
were removed from the model in a backwards manner and the model 
was refi t. Two a-priori group contrasts were specifi ed: 30 mg versus 
placebo; 60 mg versus placebo.
It is important to note that mixed-effects regression modeling 
does not place restrictions on the number of observations per indi-
vidual, so that participants with missing data at a particular assess-
ment time were not excluded from analyses. Instead, model param-
eters were estimated using all available data. Essentially, the model 
assumes that the data that are present for a given subject reasonably 
refl ect that subject’s deviation from the usual fi xed-effects regression 
part of the model (i.e. the regressors multiplied by their coeffi cients). 
In the present study, the following assessments of positive and neg-
ative affect were missing: 18 at visit 3, 24 at visit 4, 32 at visit 5, 
39 at visit 6, 51 at visit 7, 62 at visit 8, 72 at visit 9. Broken down 
by group, there were 116 total data points missing from the placebo 
group, 83 from the 30 mg group, and 99 from the 60 mg group.
Results
Preliminary analyses
Participant characteristics
Baseline smoking history and sociodemographic variables 
were compared across conditions using one way analyses of 
variance for continuously scaled variables and chi-square tests 
for differences between proportions when variables were di-
chotomous. As shown in Table 1, smokers randomized to the 
different treatment conditions showed no signifi cant differ-
ences on age, gender, baseline positive and negative affect, 
nicotine dependence, number of years smoked, cotinine level, 
and history of depression. Baseline PANAS scores are compa-
rable to those reported in other euthymic samples (Watson et 
al. 1988).
Abstinence rates
Abstinence was determined via self-report, cotinine, and car-
bon monoxide assessments collected at each visit. At visit 
5, abstinent smokers comprised 36.7% of those of placebo, 
35.1% of those on 30 mg and 46.1% of those taking 60 mg. 
At visit 6, abstinent smokers comprised 38.3% of those on 
placebo, 35.1% of the 30 mg group, and 39.7% of the 60 mg 
group. At visit 7, abstinent smokers comprised 25% of the 
placebo group, 26.3% of the 30 mg group, and 25.9% of the 
60 mg group. At visit 8, abstinent smokers comprised 26.7% 
Table 1  Baseline demographic and smoking variable means and standard deviations by condition 
 Placebo (n = 60) 30 mg (n = 57) 60 mg (n = 58)
% Female 61.7 54.4 55.2
History of depression (%) 28.4 26.3 25.8
Age 41.9 (9.3) 41.7 (9.6) 44.0 (9.5)
Baseline positive affect 33.9 (6.7) 32.1 (6.5) 31.7 (5.9)
Baseline negative affect 15.1 (3.8) 16.6 (5.8) 17.1 (4.8)
Cotinine level (ng/ml) 274.5 (135.6) 288.4 (142.6) 303.2 (178.4)
Fagerstrom 6.4 (1.8) 6.8 (1.9) 7.1 (1.8)
Number of years smoking 24.5 (10.3) 25.6 (8.8) 25.1 (8.0)
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of those on placebo 19.3% of those on 30 mg, and 29.3% 
of those on 60 mg. At visit 9, abstinent smokers comprised 
21.7% of the placebo group, 14% of the 30 mg group, and 
24.9% of the 60 mg group.
Change score derivation
Simple change score analysis (visit–baseline) measured 
change in positive and negative affect at each visit, consistent 
with our interest in examining fl uoxetine’s infl uence on acute 
changes in affect after quitting smoking and evidence that 
mood change represents a clinically relevant affective distur-
bance during nicotine abstinence (Piasecki et al. 2000). Vis-
its 1 and 2 were averaged together to create baseline positive 
and negative affect because treatment did not require smok-
ing reduction at these measurement points and fl uoxetine was 
not administered until after visit 2. Prior to creating baseline 
scores, it was established that positive and negative affect did 
not change across visits 1 and 2. Mean positive affect at vis-
its 1 and 2 was 32.27 and 32.79, respectively (P = 0.48) and 
mean negative affect at visits 1 and 2 was 15.86 and 16.52, re-
spectively (P = 0.11).
Correlation analyses
Pearson correlations were computed to identify appropriate 
covariates. The association between change in positive and 
negative affect and the following potential covariates were ex-
amined: history of depression, nicotine dependence (FTQ), 
number of cigarettes smoked daily, gender, plasma concen-
trations of fl uoxetine metabolites (composite average of vis-
its 5 and 9), and change in cotinine from baseline to each visit. 
Only nicotine dependence, fl uoxetine blood levels, and change 
in cotinine were signifi cantly correlated with change in posi-
tive and negative affect after cessation (all r<0.05), and were 
therefore retained as covariates. Associations between change 
in positive and negative affect at each visit were also exam-
ined. Correlation analysis showed that the association between 
change in positive and negative affect was moderate and sig-
nifi cant at all time points [r = –0.21 to –0.41, P<0.05], al-
though not to the extent that they appeared to refl ect the same 
construct.
Mixed linear modeling
Positive affect model
A signifi cant group by time interaction was present in the lon-
gitudinal analysis of change in positive affect (see Table 2). 
Specifi cally, the 60 mg versus placebo comparison showed a 
linear interaction with time [t(526) = 2.50, P = 0.01]. Rela-
tive to placebo, those on 60 mg fl uoxetine experienced an in-
crease in positive affect that grew across time (see Figure 1). 
There were no signifi cant differences between 30 mg and pla-
cebo. Parallel analyses using residualized positive affect as an 
outcome variable yielded the same results.
Negative affect model
The negative affect model showed a signifi cant linear [t(524) 
= –2.21, P = 0.03] and quadratic [t(524) = 2.26, P = 0.02] in-
teraction with time (see Table 3). Relative to placebo, those 
on 60 mg fl uoxetine experienced a decrease in negative affect. 
Across time, however, this advantage appeared to diminish 
Table 2  Predictors of change in positive affect from visit 3 through visit 9, determined by mixed 
linear modeling analysis with autoregressive errors 
 Variable Regression coeffi cient Standard error t 
Covariates Change in cotinine –0.18 0.11 –1.76
 Fagerstrom –0.27 0.23 –1.20
 Fluoxetine metabolites 1.17 1.17 1.00
Main effects Time –0.94 0.36 –2.61**
 (Time)2  0.14 0.05 2.74**
 30 mg –7.30 6.56 –1.11
 60 mg –7.59 7.28 –1.04
Interactions 30 mg × Time 0.46 0.28 1.62
 60 mg × Time 0.73 0.29 2.50*
*P<0.05, **P<0.01
Figure 1  Regression function showing estimated positive affect 
change by condition across time, covariate adjusted for change in co-
tinine, fl uoxetine blood levels and nicotine dependence. Distances 
represent real time. Participants quit smoking between visit 3 and 4, 
14 days after beginning of medication phase 
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(see Figure 2). There were no signifi cant differences between 
30 mg and placebo. Parallel analyses using residualized nega-
tive affect as an outcome variable yielded the same results.
Subanalyses
We ran parallel analyses among continuous abstainers versus 
non-continuous abstainers to examine whether fl uoxetine’s 
benefi cial mood effects were secondary to feelings of success 
associated with quitting smoking. Those identifi ed as continu-
ous abstainers were abstinent at visit 6 and maintained contin-
uous abstinence through visit 9. Fluoxetine produced similar 
trends in positive and negative affect in both groups. That is, 
60 mg fl uoxetine increased positive affect and decreased neg-
ative affect after quitting, regardless of smoking status. To ex-
amine the impact of smoking cessation on changes in affect 
further, continuous abstinence was statistically controlled in 
both regression models. Even after controlling for abstinence, 
those taking 60 mg fl uoxetine experienced a linear increase in 
positive affect (P = 0.01) and decrease in negative affect (lin-
ear, P = 0.04; quadratic, P = 0.04). Results suggest that pos-
itive and negative affect changes are infl uenced by fl uoxetine 
rather than feelings of success after quitting smoking.
Discussion
The current results are the fi rst to show that fl uoxetine im-
proves post-quit positive and negative mood states. The fi nd-
ings accord with growing evidence that antidepressants may 
be used to reduce affective distress following quitting smok-
ing (Hall et al. 1998; Shiffman et al. 2000; Lerman et al. 
2002). Notably, fl uoxetine produced a reduction in negative 
affect and a rise in positive affect. That observation is partic-
ularly noteworthy when considering that other antidepressants 
have simply attenuated increases in negative affect (nortripty-
line, bupropion) and decreases in positive affect (bupropion) 
while abstaining from nicotine. The current results showing 
that fl uoxetine increased post-cessation positive affect sug-
gest that the drug may be unique in not only buffering against 
an aversive mood response to nicotine abstinence, but actu-
ally producing improvement in positive affect following quit-
ting smoking.
Fluoxetine’s enhancement of positive affect is interesting 
to consider given that human pharmacology studies have fo-
cused primarily on SSRI modulation of negative affect (Zald 
and Depue 2001). The dearth of research examining SSRI in-
fl uences on positive affect may partially result from the view 
that positive mood states refl ect little more than the opposite 
of negative moods along a single affective dimension (Russell 
and Carroll 1999). Our data, however, showed that changes 
in post-quit positive and negative affect were only moderately 
intercorrelated. That fl uoxetine exerted a more sustained in-
fl uence on positive affect than on negative affect also sug-
gests that these two parameters of affective responses are at 
least partially independent. Although those on 60 mg fl uox-
etine experienced reductions in negative affect during the fi rst 
few weeks after quitting smoking, improvements in negative 
affect dissipated by end of treatment (see Figure 2). In con-
trast, fl uoxetine s infl uence on positive affect grew stronger 
across time (see Figure 1), resulting in assessments of positive 
mood that exceeded pre-quit levels. The positive affect pattern 
Table 3  Predictors of change in negative affect from visit 3 through visit 9, determined by mixed 
linear modeling analysis with autoregressive errors 
 Variable Regression coeffi cient Standard error t 
Covariates Change in cotinine 0.22 0.12 1.98*
 Fagerstrom 0.30 0.21 1.41
 Fluoxetine metabolites –1.4 1.11 –1.3
Main effects Time 0.88 0.55 1.11
 (Time)2  –0.17 0.09 –1.93
 30 mg 0.19 6.19 0.03
 60 mg –0.57 6.87 –0.08
Interactions 30 mg × Time –0.65 0.76 –0.85
 60 mg × Time –1.73 0.78 –2.21*
 30 mg × (Time)2  0.06 0.12 0.52
 60 mg × (Time)2  0.29 0.13 2.26*
*P<0.05
Figure 2  Regression function showing estimated negative affect 
change by condition across time, covariate adjusted for change in co-
tinine, fl uoxetine blood levels and nicotine dependence. Distances 
represent real time. Participants quit smoking between visit 3 and 4, 
14 days after beginning of medication phase 
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that emerged for the 60 mg group is strikingly different than 
reported losses in positive affect in the placebo group and in 
others abstaining from nicotine (Gilbert et al 1998; Lerman 
et al. 2002; Cook et al. 2003). Fluoxetine appears to have not 
only reversed typical reported losses in positive affect follow-
ing smoking, but stimulated a positive mood improvement 
that continued to grow 8 weeks after quitting smoking.
Animal models of brain reward function are relevant to 
understanding positive mood effects in humans to the extent 
that positive emotions can be viewed as subjective cues that 
motivate approach behavior toward rewards (Depue and Col-
lins 1999). Findings from animal studies indicate that fl uox-
etine heightens responsivity to rewards, and suggest dopami-
nergic (DA) and serotonergic (5-HT) mechanisms of action. 
In animal studies, nicotine abstinence leads to a decrement in 
reward functioning that is reversed or prevented by fl uoxetine 
(Harrison et al. 2001), a fi nding analogous to fl uoxetine’s en-
hancement of positive affect in the present study. Fluoxetine’s 
positive mood enhancing effects might plausibly come about 
via 5-HT/DA interaction. Fluoxetine administration directly 
enhances 5-HT activity, which has been shown to facilitate do-
pamine release in the nucleus accumbens (Benloucif and Gal-
loway 1991; De Deuwaerdere et al. 1996), and increase sensi-
tivity to reward (Sasaki-Adams and Kelley 2001). Conversely, 
decreased 5-HT release inhibits DA activity (Ichikawa et al. 
1995), a mechanism that has been linked with acquisition of 
anhedonia (Harrison et al. 2001; Zagen et al. 2001). Plausi-
bly, therefore, reduction in positive affect during nicotine de-
privation may be engendered by decreased 5-HT activity with 
consequent inhibition of DA release. We posit that a relatively 
high dose of fl uoxetine (60 mg) may be needed to induce suf-
fi cient 5-HT activation to normalize DA release in the nucleus 
accumbens, thereby increasing positive affect.
Study limitations include the selective nature of the sam-
ple in the respect that participants were motivated to quit 
smoking and generally in good physical and mental health. 
Generalizability to populations with greater physical and psy-
chological comorbidities cannot be assumed. Nor is it known 
to what degree study results would generalize to populations 
of smokers who were attempting to quit without behavioral as-
sistance. Another limitation is that other mood measures were 
not examined, potentially limiting the generalizability with re-
gard to other assessments of affect. A fi nal limitation is that 
missing data increased over time and differed between groups. 
We therefore utilized mixed linear modeling, an analytic strat-
egy designed for handling time and group differences in miss-
ing data. Random effects regression creates model parameters 
using all available data, therefore estimating rate of change for 
missing participants.
More generally, this study suggests the utility of SSRIs 
for treating not only elevated negative affect, but also defi cient 
positive affect, a common feature of depression (Clark and 
Watson 1991; Coyne 1994). In the context of smoking cessa-
tion, our data show that 60 mg fl uoxetine, relative to placebo, 
improved positive and negative affect during nicotine absti-
nence. In view of prior fi ndings that link mood problems dur-
ing smoking cessation with relapse, it is plausible that benefi -
cial effects of antidepressants on smoking cessation (Spring et 
al. 1995; Hurt et al. 1997; Hall et al. 1998; Niaura et al. 2002) 
may be modulated via effects on positive and negative affect. 
Clinically, the current fi ndings indicate that fl uoxetine is help-
ful in alleviating affective distress triggered by quitting smok-
ing, and might therefore prove helpful in preventing post-ces-
sation decline into depression (Borrelli et al. 1996; Tsoh et al. 
2002). An important question that remains to be examined in 
future research is whether fl uoxetine’s effects on post-cessa-
tion affect mediate cessation outcome.
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